Zentalis Pharmaceuticals (ZNTL) Consolidated Net Income (2022 - 2025)
Historic Consolidated Net Income for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to -$26.7 million.
- Zentalis Pharmaceuticals' Consolidated Net Income rose 3353.5% to -$26.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.3 million, marking a year-over-year increase of 1673.86%. This contributed to the annual value of -$165.9 million for FY2024, which is 3996.66% up from last year.
- Latest data reveals that Zentalis Pharmaceuticals reported Consolidated Net Income of -$26.7 million as of Q3 2025, which was up 3353.5% from -$26.9 million recorded in Q2 2025.
- In the past 5 years, Zentalis Pharmaceuticals' Consolidated Net Income ranged from a high of $10.0 million in Q1 2024 and a low of -$98.9 million during Q2 2023
- Moreover, its 4-year median value for Consolidated Net Income was -$52.1 million (2022), whereas its average is -$51.0 million.
- As far as peak fluctuations go, Zentalis Pharmaceuticals' Consolidated Net Income soared by 11647.2% in 2024, and later crashed by 58086.65% in 2025.
- Quarter analysis of 4 years shows Zentalis Pharmaceuticals' Consolidated Net Income stood at -$48.2 million in 2022, then decreased by 26.53% to -$60.9 million in 2023, then rose by 22.1% to -$47.5 million in 2024, then soared by 43.78% to -$26.7 million in 2025.
- Its last three reported values are -$26.7 million in Q3 2025, -$26.9 million for Q2 2025, and -$48.3 million during Q1 2025.